CNP Group (“CNP”) is an international manufacturer and distributor of generic pharmaceuticals with a focus on anti-infectives. In addition to antibiotics, CNP offers over-the-counter medicines and medical devices. Most of the products are manufactured at the company’s two production sites in Saarland, Germany. CNP owns marketing authorizations for approx. 400 pharmaceutical products and generates revenues of more than € 40 million with approx. 250 employees. The group is active in 19 countries.
In cooperation with the management team and supported by industry experts, capiton plans to leverage the company’s substantial local production capacity and international footprint to further strengthen CNP´s leading position in target niche markets.
capiton acquired CNP Group from the founding family together with the management team as well as senior industry experts. Financing of the transaction is provided by capiton’s current investment vehicle, capiton VI. Additional funds have been reserved to finance both organic and inorganic growth initiatives in Germany and abroad.
The transaction remains subject to approval from competition authorities. Sellers and buyers have agreed not to disclose the financial terms of the transaction.
capiton was advised by Hampton Pharma and Fidelio Healthcare Partners (Commercial), PwC (Financial), EY (Tax), BMH (Legal), Straeter Rechtsanwaelte (Pharma law), Dr. Regenold GmbH (Regulatory and technical due diligence), Willis Tower Watson (Insurance), AvS (Management audit) and Tauw (ESG & EDD).